KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Operating Leases: 2020-2024

Historic Operating Leases for AbCellera Biologics (ABCL) over the last 5 years, with Dec 2024 value amounting to $60.7 million.

  • AbCellera Biologics' Operating Leases rose 106.80% to $137.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $137.1 million, marking a year-over-year increase of 106.80%. This contributed to the annual value of $60.7 million for FY2024, which is 21.50% down from last year.
  • Per AbCellera Biologics' latest filing, its Operating Leases stood at $60.7 million for FY2024, which was down 21.50% from $77.4 million recorded in FY2023.
  • Over the past 5 years, AbCellera Biologics' Operating Leases peaked at $82.3 million during FY2022, and registered a low of $3.7 million during FY2020.
  • Over the past 3 years, AbCellera Biologics' median Operating Leases value was $77.4 million (recorded in 2023), while the average stood at $73.5 million.
  • Its Operating Leases has fluctuated over the past 5 years, first spiked by 880.16% in 2021, then dropped by 21.50% in 2024.
  • Yearly analysis of 5 years shows AbCellera Biologics' Operating Leases stood at $3.7 million in 2020, then surged by 880.16% to $36.4 million in 2021, then skyrocketed by 125.90% to $82.3 million in 2022, then declined by 5.93% to $77.4 million in 2023, then decreased by 21.50% to $60.7 million in 2024.